Validating antibodies for detecting modified proteins
Official title: Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.
Funded at Abbratech, INC. · NIH-10931606 · Data updated 2026-11-12
This study is working to make sure that the tools scientists use to find certain proteins in the lab are more accurate and reliable, which will help improve research and treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project start | April 1, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,121,971 |
| NIH project number | 5R44GM146473-03 |
| Project ID | NIH-10931606 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include patients with conditions that involve post-translationally modified proteins, such as certain cancers.
✕Less likely to help
Patients who do not have conditions related to protein modifications or who are not involved in biomedical research may not receive direct benefits from this research.
What this research studies
This research focuses on improving the accuracy and reliability of antibodies used in biomedical research to detect specific proteins that have undergone post-translational modifications. The project aims to validate these antibodies through innovative methods, including a technique called MILKSHAKE and a new tool named Sundae, which assesses antibody specificity. By extending previous work, the researchers will analyze various modifications and enhance the detection of glycosylated proteins, which are often difficult to identify. This work is crucial for ensuring that researchers can trust the results of their experiments, ultimately benefiting patient care and treatment development.
Why it matters
Potential benefit: If successful, this research could lead to more reliable diagnostic tools and therapies for patients with various diseases, including cancers.
How similar studies have gone: Other research has shown success in validating antibodies for specific applications, but this approach to post-translational modifications is innovative and may provide new insights.
Where this research is happening
-
Abbratech, INC.
Branford, United States Active
Researchers
- Principal investigator: Weiner, Michael P — Abbratech, INC.
- Study coordinator: Weiner, Michael P
Related research
Other NIH-funded projects on the same topics.
-
Antibody Platform for Protein Isoform Splice-Junctions
A fast-track NIH grant aims to create antibodies that specifically recognize unique splice-junctions in proteins, helping to better understand and treat diseases linked to alternative splicing.
-
Creating special antibodies to find disease-related protein changes
This project aims to create new tools, called antibodies, that can find specific changes in proteins linked to various diseases, including cancer.
-
Developing antibodies to fight COVID-19 using advanced technology
This study is working on developing special antibodies that can fight the COVID-19 virus, using a new method to make sure they can keep up with any changes the virus might make, which could help improve treatments for COVID-19 and other infections.
-
Developing antibodies to target specific cancer mutations
This study is working on new antibodies that can help the immune system better recognize and attack cancer cells with a specific KRAS mutation, aiming to make treatments more effective and safer for patients with these types of cancers.
-
Developing antibodies to target specific protein splice variants
This study is working on a new way to find and test special antibodies that can help us understand and treat diseases like cancer by focusing on how proteins are made in different forms, which can change how they behave in the body.
-
A platform for quickly creating and testing antibodies
This study is working on a new way to quickly create and test special proteins called antibodies that can help treat diseases, so patients can get better treatments faster and more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.